Article
Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.
Medicine - 23 Oct 2020
Li Juan, Wu Dong-Bo, Jiang Wei, Chen Xue-Bin, Xiao Gui-Bao, Wang Yong-Hong, Wang Meng-Lan, Tao Ya-Chao, Chen En-Qiang
Abstract excerpt
Several new, pangenotypic direct-acting antiviral agents (DAAs) have been approved, may reduce the need for genotyping to guide therapy decisions for patients with chronic hepatitis C (CHC).This study aimed to investigate the efficacy and safety of Sofosbuvir (SOF)-based pangenotypic DAAs therapy for CHC patients without genotype (GT determination in the real-world practice.This retrospective cohort study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.